Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P60484: Variant p.Ser170Arg

Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Gene: PTEN
Feedback?
Variant information Variant position: help 170
Type of variant: help LP/P [Disclaimer]
Residue change: help From Serine (S) to Arginine (R) at position 170 (S170R, p.Ser170Arg).
Physico-chemical properties: help Change from small size and polar (S) to large size and basic (R)
BLOSUM score: help -1
Variant description: help In CWS1; severely reduced protein phosphatase activity; loss of phosphatase activity towards Ins(1,3,4,5)P4.
Other resources: help


Sequence information Variant position: help 170
Protein sequence length: help 403
Location on the sequence: help EALDFYGEVRTRDKKGVTIP S QRRYVYYYSYLLKNHLDYRP
Residue conservation: help
Human                         EALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRP

                              EALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRP

Mouse                         EALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRP

Rat                           EALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRP

Xenopus laevis                EALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNSLEYRP

Caenorhabditis elegans        QILDYYSIIRTKNNKGVTIPSQRRYIYYYHKLRERELNYLP

Slime mold                    DSLRFYAALRTYNQKGVTIPSQIRYVGYFGRSIRESIKYVP

Fission yeast                 QSLELYTEKRMVRGHGLTISSQIRYVYYIE-ILKQFPNY--

Sequence annotation in neighborhood: help
TypePositionsDescription
Chain 2 – 403 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Domain 14 – 185 Phosphatase tensin-type
Alternative sequence 165 – 190 GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMDVIAP. In isoform 3.
Mutagenesis 167 – 167 T -> AD. 60% reduction in phosphatase activity towards PtdIns(3,4,5)P3.
Mutagenesis 171 – 171 Q -> AE. 75% reduction in phosphatase activity towards PtdIns(3,4,5)P3.
Helix 169 – 184



Literature citations
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.
Myers M.P.; Stolarov J.P.; Eng C.; Li J.; Wang S.I.; Wigler M.H.; Parsons R.; Tonks N.K.;
Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997)
Cited for: FUNCTION; CATALYTIC ACTIVITY; CHARACTERIZATION OF VARIANTS GLIOMA TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129; PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ ARG-170; Germline mutations in PTEN are present in Bannayan-Zonana syndrome.
Marsh D.J.; Dahia P.L.M.; Zheng Z.; Liaw D.; Parsons R.; Gorlin R.J.; Eng C.;
Nat. Genet. 16:333-334(1997)
Cited for: VARIANT CWS1 ARG-170; PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
Marsh D.J.; Kum J.B.; Lunetta K.L.; Bennett M.J.; Gorlin R.J.; Ahmed S.F.; Bodurtha J.; Crowe C.; Curtis M.A.; Dasouki M.; Dunn T.; Feit H.; Geraghty M.T.; Graham J.M. Jr.; Hodgson S.V.; Hunter A.; Korf B.R.; Manchester D.; Miesfeldt S.; Murday V.A.; Nathanson K.L.; Parisi M.; Pober B.; Romano C.; Tolmie J.L.; Trembath R.; Winter R.M.; Zackai E.H.; Zori R.T.; Weng L.-P.; Dahia P.L.M.; Eng C.;
Hum. Mol. Genet. 8:1461-1472(1999)
Cited for: VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246; Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.
Han S.-Y.; Kato H.; Kato S.; Suzuki T.; Shibata H.; Ishii S.; Shiiba K.; Matsuno S.; Kanamaru R.; Ishioka C.;
Cancer Res. 60:3147-3151(2000)
Cited for: CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; GLY-369 AND ILE-401; CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347; Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography.
Marsh D.J.; Theodosopoulos G.; Howell V.; Richardson A.-L.; Benn D.E.; Proos A.L.; Eng C.; Robinson B.G.;
Neoplasia 3:236-244(2001)
Cited for: VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.